biostudies-literatureUnknown9(7)Fraccaroli A<h4>Abstract</h4>Whether patients with acute myeloid leukemia (AML) harboring nucleophosmin mutations (NPM1mut) and measurable residual disease (MRD) should undergo allogeneic stem cell transplantation (allo-SCT) in complete remission (CR) remains debatable. This study assessed whether bone marrow (BM) NPM1mut MRD, detected via quantitative reverse transcription polymerase chain reaction (qRT-PCR) with 10-5 sensitivity, influences allo-SCT benefit. Data from 4 German transplantation centers included 174 patients with AML NPM1mut who underwent first allo-SCT between 2011 and 2022. Among 122 patients transplanted in CR, pre-allo-SCT MRD was positive in 54%. After allo-SCT, BM MRD negativity increased from 65% (day +30) to 73% (day +100), with FMS-like tyrosine kinase 3-internal tandem duplicBlood advances1630-1641https://www.ebi.ac.uk/biostudies/studies/S-EPMC11995096biostudies-literaturePretransplant MRD does not seem to affect survival in NPM1-mutated AML undergoing allogeneic stem cell transplantation.PMC11995096Schmid CSpiekermann KHirschbuhl KHaebe SHerold TDrolle HJurinovic VVerbeek MTischer JKoch KBreitkopf SDufour AMetzeler KHHentrich MFraccaroli AHausmann ARothenberg-Thurley MStauffer EfalsePretransplant MRD does not seem to affect survival in NPM1-mutated AML undergoing allogeneic stem cell transplantation.<h4>Abstract</h4>Whether patients with acute myeloid leukemia (AML) harboring nucleophosmin mutations (NPM1mut) and measurable residual disease (MRD) should undergo allogeneic stem cell transplantation (allo-SCT) in complete remission (CR) remains debatable. This study assessed whether bone marrow (BM) NPM1mut MRD, detected via quantitative reverse transcription polymerase chain reaction (qRT-PCR) with 10-5 sensitivity, influences allo-SCT benefit. Data from 4 German transplantation centers included 174 patients with AML NPM1mut who underwent first allo-SCT between 2011 and 2022. Among 122 patients transplanted in CR, pre-allo-SCT MRD was positive in 54%. After allo-SCT, BM MRD negativity increased from 65% (day +30) to 73% (day +100), with FMS-like tyrosine kinase 3-internal tandem duplic2025-01-01T00:00:00Z2025 Apr2025-07-03T03:06:45.093Z2025-07-03T03:06:45.093ZS-EPMC119950963990310510.1182/bloodadvances.2024014767